ストックスクリーナーアプリを入手
0.262
3.56%
0.009
前日終値:
$0.253
開ける：
$0.253
24時間の取引高:
264.36K
Relative Volume:
0.58
時価総額：
$25.88M
収益：
$1.20M
当期純損益:
$-5.34M
株価収益率:
-4.2395
EPS:
-0.0618
ネットキャッシュフロー:
$-6.27M
1週間 パフォーマンス:
-4.90%
1か月 パフォーマンス:
-9.69%
6か月 パフォーマンス:
-32.96%
1年 パフォーマンス:
-14.32%
1日の値動き範囲:
$0.25
$0.2734
1週間の範囲:
$0.25
$0.29
52週間の値動き範囲:
$0.242
$0.4985
IGC Pharma Inc Stock (IGC) Company Profile
Compare IGC vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IGC
IGC Pharma Inc
|
0.262 | 25.00M | 1.20M | -5.34M | -6.27M | -0.0618 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
IGC Pharma Inc (IGC) 最新ニュース
New to The Street and IGC Pharma (NYSE American:IGC) Launch Strategic 12-Part National Media Partnership to Accelerate Investor Awareness and Market Positioning - The Daily Corinthian
Macro Review: Is IGC Pharma Inc likely to announce a buybackChart Signals & Verified Swing Trading Watchlists - baoquankhu1.vn
If You Invested $1,000 in IGC Pharma Inc (IGC) - Stock Titan
Growth Report: Does IGC Pharma Inc stock benefit from AI growthEntry Point & Technical Pattern Based Signals - baoquankhu1.vn
Ascendiant Capital maintains IGC Pharma (IGC) buy recommendation - MSN
Fund Flows: Can IGC Pharma Inc ride the EV wave2026 PreEarnings & Daily Technical Stock Forecast Reports - baoquankhu1.vn
India Globalization Capital, Inc.: Fundamental Analysis and Financial Ratings | IGC | US45408X3089 - marketscreener.com
IGC Pharma earnings matched, revenue fell short of estimates By Investing.com - Investing.com Canada
IGC Pharma Reports Financial Results and Clinical Progress for the Period Ended December 31, 2025 - Hastings Tribune
IGC Achieves Major Milestone in Alzheimer's Trial Amid Financial Loss - GuruFocus
IGC Pharma’s AI-Driven Innovations and Patent Portfolio for Alzheimer’s Disease and Neuropsychiatric Treatments - Minichart
IGC to Showcase AI Platform for Alzheimer's Research at 2026 Con - GuruFocus
IGC Pharma : Annual Transition Report (Form 10-KT) - marketscreener.com
IGC Pharma (IGC) Transition 10-KT: CALMA Phase 2 shows interim agitation improvements - Stock Titan
IGC Pharma to Showcase AI Platform with Alzheimer’s Disease Data Initiative at ADPD 2026 - BioSpace
IGC Pharma to Showcase AI Platform with Alzheimer's Disease Data Initiative at ADPD 2026 - PharmiWeb.com
IGC Pharma to Showcase AI Platform With Alzheimer's Disease Data Initiative at ADPD 2026 - 富途牛牛
CEO Change: What is the Moat Score of IGC Pharma IncMarket Activity Recap & Real-Time Volume Analysis Alerts - baoquankhu1.vn
IGC Pharma (NYSEAMERICAN:IGC) Stock Price Down 1.2% – Time to Sell? - Defense World
IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial - Nasdaq
IGC Pharma Secures New Debt Financing for Liquidity - The Globe and Mail
IGC Pharma Secures ~$526K in Financing, Including Default-Convertible Note With Vanquish - TradingView
IGC Pharma (NYSE: IGC) raises cash via discounted note and $219,000 loan - Stock Titan
How IGC Pharma Inc. stock compares to growth peersDollar Strength & Smart Money Movement Tracker - Naître et grandir
EPS Watch: Should value investors consider IGC Pharma IncJuly 2025 Setups & Fast Momentum Entry Tips - baoquankhu1.vn
IGC Pharma, Inc. announced that it has received $0.307 million in funding - marketscreener.com
IGC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
IGC Should I Buy - Intellectia AI
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Suppo - PharmiWeb.com
IGC Pharma Files Utility Patent Applications Covering AI-Based Data Harmonization Architecture Supporting Alzheimer's Research - Nasdaq
IGC PE Ratio & Valuation, Is IGC Overvalued - Intellectia AI
FOMO Trade: What is the Moat Score of IGC Pharma IncBond Market & Verified Momentum Stock Ideas - baoquankhu1.vn
Trend Report: What is the Moat Score of IGC Pharma IncJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
IGC Pharma Notes Updated Research Coverage from Ascendiant Capital Markets - The Globe and Mail
Aug Final Week: Is IGC Pharma Inc a cyclical or defensive stockWatch List & Real-Time Sentiment Analysis - baoquankhu1.vn
IGC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
IGC Pharma expands Phase 2 CALMA trial with new clinical site - Yahoo Finance
IGC Enhances Alzheimer's Trial with New Clinical Research Collab - GuruFocus
Miami neurology network joins Alzheimer’s agitation drug trial - Stock Titan
Will IGC Pharma Inc. stock go up in YEARDay Trade & Daily Momentum Trading Reports - mfd.ru
Trend Review: Will IGC Pharma Inc benefit from green energy policiesJuly 2025 PreEarnings & Weekly Watchlist of Top Performers - baoquankhu1.vn
IGC: CALMA trial nears completion and MINT-AD AI platform set for beta launch amid favorable regulations - TradingView
IGC: Alzheimer's drug trial nears completion as AI dementia tool readies for beta launch - TradingView
Is IGC Pharma Inc. stock a buy before product launchesJuly 2025 Movers & Long Hold Capital Preservation Tips - mfd.ru
IGC Pharma Secures North American Composition Protection for IGC-AD1 as Phase 2 CALMA Enrollment Advances - GuruFocus
Low-dose THC Alzheimer’s drug from IGC wins key North America patent - Stock Titan
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets - Finviz
Is IGC Pharma Inc. likely to announce a buybackJuly 2025 Market Mood & Daily Entry Point Alerts - mfd.ru
Aug Catalysts: Should I trade or invest in IGC Pharma IncJuly 2025 Intraday Action & Stepwise Swing Trade Plans - baoquankhu1.vn
Why IGC Pharma Inc. (IGS1) stock could rally stronglyJuly 2025 Breakouts & Accurate Entry and Exit Point Alerts - mfd.ru
IGC Pharma Announces Equity Research Update by Alliance Global Partners - BioSpace
IGC Pharma Inc (IGC) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):